Psychedelic-assisted therapy, minus the hype.
An independent weekly briefing on research, regulation and business in psychedelic medicine worldwide, with the UK & Europe angle nobody else covers, built for clinicians, researchers, clinic operators and investors. Every claim links to a primary source.
Get the Thursday briefing
One email a week. Five-minute read. Free.
Subscribe free →Latest issue
The first half of every issue is free to read here. See all issues →
A psilocin drug passes its first Phase 3, the FDA's fast lane for psilocybin is in doubt, and Czechia's first psilocybin patients slip to 2027
Issue #4: Helus's HLP003 meets its Phase 3 endpoint with three serious adverse events, the FDA's fast lane for the psilocybin reviews is in doubt, Congress asks whether the VA is ready, Czechia's first patients may wait until 2027, a European early-access initiative, and new guides to Switzerland an
Guides
Plain-English explainers on law, trials and access, with every claim linked to a primary source. All guides →
Psilocybin clinical trials in the UK: what is recruiting and how to join
Recruiting UK psilocybin trials from public registries, updated weekly, plus how to find and join a trial.
Is psychedelic therapy legal in the UK?
Psilocybin, MDMA, LSD, DMT and ketamine under UK law, what the NHS offers, and what may change. Every claim sourced.
When will psilocybin, MDMA or LSD be approved in Europe? EMA tracker 2026
Where psilocybin, MDMA and LSD medicines stand with EMA, MHRA and FDA, plus national routes in Czechia, Germany and Switzerland.
Legal psilocybin therapy in Czechia (2026): who qualifies and when it starts
Czechia's medical psilocybin framework: who can prescribe it, who qualifies, the dose rules, and when treatment is expected to start.
Psilocybin therapy in Germany (2026): the compassionate use programme explained
Germany's psilocybin compassionate use programme at ZI Mannheim and OVID Berlin: the law, who qualifies, costs, evidence and trials.
Psilocybin-Therapie in Deutschland (2026): das Härtefallprogramm erklärt
Auf Deutsch: das Arzneimittel-Härtefallprogramm mit Psilocybin, Rechtslage, Voraussetzungen, Kosten und Studien.
Psychedelic therapist training in Europe (2026): courses, entry rules and what they qualify you for
No EU or UK licence exists: the rules in Czechia, Switzerland, Germany and the UK, and the main training programmes compared.
Psychedelic therapy in Switzerland (2026): limited medical use, who qualifies and what it costs
Limited medical use of psilocybin, MDMA and LSD in Switzerland: FOPH licences for Swiss residents only, who qualifies, costs, numbers and trials.
Psychedelic trials recruiting in Europe (2026): psilocybin, MDMA, LSD and ketamine studies by country
Psychedelic and ketamine-assisted therapy trials recruiting in the UK and Europe, filterable by country and substance, from public registries.
Approval tracker
Where key psychedelic and related programmes stand with regulators. Last reviewed 19 Nov 2026. "—" = not applicable / no sourced status.
| Programme | Indication | Stage | US FDA | UK MHRA | EU / Europe | Updated | Sources |
|---|---|---|---|---|---|---|---|
| COMP360 (synthetic psilocybin)Compass Pathways (London/New York) | Treatment-resistant depression (TRD) | Filing (US) | NDA submission completed 9 Nov 2026 (company); no FDA acceptance or decision date announced as of 19 Nov (on 18 Nov management said it expects a PDUFA date to be assigned soon and does not expect an advisory committee); holds a Commissioner's National Priority Voucher (review target 1–2 months), but Reuters reported on 12 Nov that FDA has shelved the voucher pilot (HHS says the work is ongoing and FDA staff continue to evaluate applications already granted a voucher); launch expected H1 2027 if approved, after DEA and state rescheduling | ILAP designation for TRD (company statement); not authorised | No EMA application reported Breakthrough Therapy (US); National Priority Voucher (US, Apr 2026); ICER cost-effectiveness review: revised scope published 18 Nov 2026 (comparators esketamine, IV ketamine, rTMS; public meeting 20 May 2027) |
[1][2][3][4][5][6][7][8][9][10][11] | |
| Psilocybin (synthetic)Usona Institute (non-profit, Wisconsin) | Major depressive disorder (MDD) | Filing (US) | NDA submission completed (reported by Psychedelic Alpha, 2 Nov 2026; Usona declined to comment); Breakthrough Therapy since 2019; National Priority Voucher (reported), whose pilot Reuters reported shelved on 12 Nov (HHS says ongoing) | Not reported | No EMA application reported | [1][2][3][4] | |
| MDMA-assisted therapyResilient Pharmaceuticals (formerly MAPS PBC / Lykos) | PTSD | Resubmitted (US) | NDA resubmitted Aug 2026 without new Phase 3 (reported; FDA acceptance/PDUFA date not disclosed). Prior CRL 9 Aug 2024 | Not authorised; MDMA Schedule 1 | No EMA application visible; investigator-led trials (Netherlands Phase II approved Aug 2026; Norway Phase 2 pilot Jul 2026) Australia: Authorised Prescriber pathway (psychiatrists) since 1 Jul 2023. Switzerland: limited medical use. Canada: Optimi Health says a Health Canada-cleared Phase 3 of its own MDMA-assisted therapy (OPTI-201) in 100 veterans and front-line workers with PTSD is expected to start in 2027 (company, 18 Nov 2026) |
[1][2][3][4][5][6] | |
| Esketamine nasal spray (Spravato)Janssen (Johnson & Johnson) | TRD (with SSRI/SNRI) | Approved | Approved (the reference TRD product Compass benchmarks pricing against) | Licensed, but NICE TA854 does not recommend routine NHS use | Authorised EU-wide 18 Dec 2019; reimbursed in 13 European countries per PsyAccess Germany: post-dose observation billing kept restricted to psychiatric specialties (13 Aug 2026) |
[1][2][3][4] | |
| DT120 ODT (lysergide / LSD; formerly MM120)Definium Therapeutics (formerly MindMed) | GAD; MDD; PTSD (Phase 3 planned 2027) | Phase 3 | Phase 3: positive Voyage & Panorama (GAD) and Emerge (MDD); Ascend (MDD) enrolling, topline 2027; Breakthrough Therapy for GAD and MDD; NDA (GAD) planned H1 2027; Phase 3 Haven (PTSD) to start 2027 | Not reported | Panorama (GAD) enrolled in US and Europe; no EMA filing reported | [1][2][3] | |
| HLP003 (deuterated psilocin; formerly CYB003)Helus Pharma (formerly Cybin) | Adjunctive MDD | Phase 3 | Phase 3 APPROACH (n=222) positive topline 16 Nov 2026: −7.6 points vs placebo on MADRS at week 6 and −7.0 at week 12 (p<0.0001); three treatment-related serious adverse events (company; BioSpace reports two cases of depression and one suicide attempt); EMBRACE topline expected Q4 2027; NDA expected 2028; Breakthrough Therapy | Not reported (EMBRACE Phase 3 has UK sites) | Not reported (EMBRACE Phase 3 has sites in Czechia, Germany, Greece, Ireland and Poland) HLP004 (deuterated DMT, GAD) Phase II planned Q1 2027 |
[1][2][3][4] | |
| BPL-003 (intranasal mebufotenin / 5-MeO-DMT)AtaiBeckley (Eli Lilly subsidiary since 11 Sep 2026; Beckley Psytech roots, UK) | TRD | Phase 3 (starting) | Phase 3 programme (ReConnection-1/-2) initiation guided for Q2 2026 after End-of-Phase 2 meeting; no registry record seen as of 15 Sep 2026 (Psychedelic Brief) | Not reported | Not reported Phase 2b results published in JAMA 26 Oct 2026 (193 analysed; 12 mg beat 0.3 mg control on MADRS at day 29, difference −5.3 points). Lilly CVR milestone tied to US approval + DEA rescheduling |
[1][2][3][4][5][6] | |
| GH001 (inhaled mebufotenin / 5-MeO-DMT)GH Research (Dublin) | TRD | Pre-Phase 3 | Positive initial FDA feedback on TRD pivotal design (one fixed dose per visit via new aerosol device, MADRS at week 4); End-of-Phase 2 meeting expected Q1 2027, pivotal start shortly after; postpartum depression pivotal targeted H2 2027 (company, 13 Nov 2026) | Phase 1 device study run in UK (completed) | Not reported | [1][2][3][4] | |
| Bretisilocin (GM-2505; short-acting 5-HT2A agonist)AbbVie (acquired from Gilgamesh Pharmaceuticals, 2025) | Major depressive disorder (MDD) | Phase 2 | Phase 2a (NCT06236880) completed; no Phase 3 record found on ClinicalTrials.gov (checked 28 Oct 2026) | Phase 2a ran at UK sites (NCT06236880); not authorised | PRIME eligibility granted Feb 2026 (first psychedelic in PRIME) – not an approval or marketing application | [1][2][3] | |
| Psilocybin 25 mg (PsiDeR trial)King's College London / South London and Maudsley NHS FT (NIHR-funded) | TRD | Phase 2 (academic) | — | Phase 2 feasibility RCT (n=60) positive, published Nature Medicine Aug 2026; psilocybin remains Schedule 1 | — Academic programme |
[1] | |
| Psilocybin (national medical framework)Czech Republic (law 270/2025 Sb.) | Defined severe-depression indications | National access (rollout) | — | — | National route, not EMA: framework in force 1 Jan 2026 (Act 270/2025, Gov. Regulation 552/2025); not yet treating outside trials; a psychologist working on NUDZ psilocybin trials told Flowee (18 Nov 2026) that first patients are realistic in 2027, citing difficulty obtaining the substance and insurer arrangements still being set up | [1][2][3][4][5][6] | |
| Psilocybin compassionate use programmeGermany (BfArM; ZI Mannheim & OVID Berlin) | TRD | Compassionate use | — | — | National CUP approved 11 Jul 2025; renewed notification 18 Jun 2026, runs to 17 Jun 2027 (BfArM list) First patient treated in Berlin on 1 Apr 2026; each site expected about 20 patients by end of 2026; statutory health insurance does not cover the dosing day (reported Oct 2026) |
[1][2][3][4][5] | |
| LSD, MDMA & psilocybin (limited medical use)Switzerland (FOPH exceptional licences, Narcotics Act art. 8(5)) | Individual patients, when other treatments are exhausted | Limited medical use | — | — | Not EU: case-by-case exceptional licence per patient, applied for by the treating doctor Licences only for doctors authorised to practise in Switzerland, for patients resident in Switzerland. 2024: about 100 licensed doctors, 723 patients (psilocybin 348, MDMA 245, LSD 130), about 1,660 sessions; not covered by basic health insurance |
[1][2][3][4][5][6] | |
| Psilocybin & MDMA (Authorised Prescriber)Australia (TGA) | TRD (psilocybin); PTSD (MDMA) | Restricted prescribing | — | — | — Schedule 8 for these uses since 1 Jul 2023; psychiatrists need HREC approval + TGA authorisation |
[1] | |
| IbogaineUS HHS-funded trials (OUD, PTSD) | Opioid use disorder; PTSD | Pre-clinical / early phase | FDA RFI on early-phase trial design (5 Oct 2026; comments due 20 Nov 2026). HHS/ARPA-H committed up to $4.9M over five years (12 Nov 2026) for preparatory work towards IND applications and a domestic ibogaine supply for PTSD; it does not fund treatment or authorise trials | — | — DEA proposed raising the 2027 ibogaine production quota from 210 g to 12,002 g (10 Nov 2026; comments due 10 Dec) |
[1][2][3][4][5] |
Open the full tracker: sources for every row, Q&A and CSV/JSON download →
About
Evidence first
We summarise regulators, trial registries, peer-reviewed papers and company filings, and we link every claim. Corrections are published openly.
Global, with a UK & Europe lens
We cover the big stories worldwide, from the FDA to the TGA. Most coverage stops at the US, so we also explain what MHRA, NICE, EMA and national programmes mean for the UK and Europe.
Independent
Published by Psyche Vibes Ltd, London. Sponsorships are always clearly labelled and never influence editorial content or the tracker.